Welcome to our dedicated page for Waterdrop American news (Ticker: WDH), a resource for investors and traders seeking the latest updates and insights on Waterdrop American stock.
Waterdrop Inc. reports recurring developments for its NYSE-listed American depositary shares and its technology platform for insurance and healthcare services. Company news centers on unaudited quarterly and fiscal results, insurance-related revenue, cash dividends, ADS repurchases, and annual Form 20-F reporting.
Operational updates also cover Waterdrop Medical Crowdfunding, including risk-control and donor-transparency systems, and the E-Find Platform, the company’s digital clinical trial solution for patient enrollment and drug-patient matching. Product and technology updates include insurance plan launches, data infrastructure, automated review tools, and medical knowledge graph applications.
Waterdrop Inc. (WDH) reported strong unaudited Q2 2026 results with rapid revenue and profit growth.
For the quarter ended June 30, 2026, operating revenue reached RMB1,448.2 million, up 72.8% year-over-year, while net profit attributable to ordinary shareholders was RMB125.8 million, marking 18 consecutive profitable quarters. As of August 31, 2026, the company had cumulatively repurchased about 62.9 million ADSs from the open market.
Insurance-related revenue grew 80.5% year-over-year and insurance business operating profit rose to RMB183.6 million, up 20% quarter-over-quarter. Waterdrop highlighted rising AI penetration, with premiums facilitated by its “AI Medical Insurance Expert” increasing 25.6% quarter-over-quarter and first-year premiums for long-term insurance up 33.4% quarter-over-quarter.
The E-Find digital clinical trial platform generated Q2 net revenue of RMB35.2 million, up 26.8% year-over-year, partnering with 255 pharma companies and CROs and having cumulatively delivered 1,873 clinical trial projects involving 17,052 enrolled patients.
Waterdrop (WDH) reported unaudited second quarter 2026 results and announced a cash dividend and new share repurchase program.
Net operating revenue rose 72.8% year-over-year to RMB1,448.2 million, with insurance-related income up 80.5% to RMB1,333.2 million. Operating profit increased to RMB111.3 million, up 14.3% year-over-year and 39.2% quarter-over-quarter. Digital clinical trial solution income grew 26.8% year-over-year to RMB35.2 million, while crowdfunding service fees declined 5.7% to RMB63.6 million.
Net profit attributable to ordinary shareholders was RMB125.8 million, down from RMB140.2 million a year earlier. Cash position was RMB2,652.7 million as of June 30, 2026, versus RMB3,249.0 million at year-end 2025.
The board approved a US$0.03 per ADS cash dividend (about US$10.8 million total) and authorized a new share repurchase program of up to US$50 million through September 10, 2027.
Waterdrop (NYSE: WDH) announced it will release unaudited financial results for the quarter ended June 30, 2026 before U.S. markets open on Tuesday, September 8, 2026.
Management will host an earnings conference call on September 8, 2026 at 8:00 AM U.S. Eastern Time (8:00 PM Beijing/Hong Kong Time). Investors can join via international, U.S. toll-free, Hong Kong, or Mainland China dial-in numbers using Elite Entry Number 5895694, or access a live and archived webcast through Waterdrop’s investor relations website.
Telephone replays will be available until September 15, 2026 using replay access code 6264481.
Waterdrop (NYSE: WDH) appointed Ms. Qianfei Chang as an independent director, effective July 1, 2026, replacing Mr. Heping Feng.
She will chair the audit committee and join the compensation and nominating committees. Mr. Feng resigned for personal reasons, with no dispute or disagreement with the company reported.
Waterdrop (NYSE: WDH) reported unaudited Q1 2026 net operating revenue of RMB1,242.2 million, up 64.8% year-over-year, and net profit attributable to ordinary shareholders of RMB98.4 million, its 17th consecutive profitable quarter.
Insurance-related income rose 74.1% year-over-year, AI tools supported premium growth, E-Find clinical trial solutions revenue reached RMB24.2 million, and cumulative share repurchases totaled about 61.8 million ADSs.
Waterdrop (NYSE: WDH) reported unaudited Q1 2026 results with net operating revenue of RMB1,242.2 million, up 64.8% year-over-year but down 12.0% quarter-over-quarter. Insurance-related income rose 74.1% to RMB1,145.8 million.
Operating profit reached RMB80.0 million, net profit was RMB98.4 million, and cash position stood at RMB2,880.7 million. The company continued AI deployment, expanded clinical trial enrollment, and, by May 31, 2026, had repurchased 61.8 million ADSs for US$120.1 million and paid a US$10.8 million dividend.
Waterdrop (NYSE: WDH) will release its unaudited Q1 2026 financial results before U.S. markets open on Tuesday, June 16, 2026, for the quarter ended March 31, 2026.
Management will host an earnings conference call with Chinese and English listen-only lines and webcast replays.
Waterdrop (NYSE: WDH) filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the SEC on April 28, 2026. The report, including audited consolidated financial statements, is available on the company's investor relations website and the SEC's website.
Shareholders may request a free hard copy by contacting the IR department at IR@shuidi-inc.com.
Waterdrop (NYSE: WDH) reported strong Q4 and full‑year 2025 results: Q4 net operating revenue RMB1,411.2M (+105.5% YoY) and Q4 net profit attributable to shareholders RMB162.1M (+62.7% YoY). For 2025, revenue was RMB3,977.8M (+43.5% YoY) and net profit RMB568.9M.
The company held RMB3,249.0M cash at year-end, repurchased ~60.7M ADS by Feb 2026, and approved a ~US$10.8M cash dividend. Insurance operating profit was RMB644.9M; medical crowdfunding raised RMB72.3B for 3.68M patients. E-Find enrolled 14,555 patients into 1,611 trials.
Waterdrop (NYSE: WDH) reported strong fourth-quarter and full-year 2025 results and declared a cash dividend. Q4 net operating revenue rose 105.5% YoY to RMB1,411.2 million; Q4 net profit attributable to ordinary shareholders was RMB162.1 million, up 62.7% YoY. The company announced cumulative repurchases of ~60.7 million ADSs (~US$118.1 million) and a board‑approved cash dividend of ~US$10.8 million.
Management highlighted AI deployment across insurance, fraud controls for medical crowdfunding, and a patented intelligent drug‑patient matching technology supporting digital clinical trial growth.